Skip to main content
Pharnext logo

Pharnext — Investor Relations & Filings

Ticker · ALPHA ISIN · FR0011191287 LEI · 969500KJGF9ZUYXSMJ27 Euronext Growth Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2023-04-28 Earnings Release
Country FR France
Listing Euronext Growth ALPHA

About Pharnext

https://pharnext.com/

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Recent filings

Filing Released Lang Actions
Pharnext annonce ses résultats financiers de l'exercice 2022, une année pivot dans l'histoire de la société
Earnings Release Classification · 1% confidence The document is titled "Communiqué de presse" and explicitly announces "Pharnext annonce ses résultats financiers de l'exercice 2022" (Pharnext announces its financial results for the 2022 fiscal year). It provides key financial highlights in a table (Résultats en k€ for 2021 and 2022) and discusses operational performance, financing, and governance changes related to the fiscal year end. This structure—a press release summarizing annual financial performance—is characteristic of an Earnings Release (ER). Although it covers the full year (like a 10-K), the format is a brief announcement summarizing results, not the comprehensive statutory report itself. The text also mentions that the full annual financial report will be published later, confirming this document is the initial release of the results. FY 2022
2023-04-28 French
Pharnext soutient la conférence en ligne 2023 de CMTUK, l'association caritative dédiée aux patients atteints de la maladie de Charcot-Marie-Tooth au Royaume Uni
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces Pharnext's support for the CMTUK 2023 online conference, detailing the event dates and the company's drug candidate PXT3003 status. This is a general corporate announcement regarding an event participation and company pipeline update, not a formal regulatory filing like a 10-K, an Earnings Release (ER), or a specific financial report (IR, AR). Since it is a press release announcing corporate activity and updates, and it does not fit the specific categories like AGM-R, 10-K, ER, or CT, the most appropriate general category for a non-standard corporate announcement is Regulatory Filings (RNS), which serves as a broad category for miscellaneous regulatory/corporate news releases that aren't covered by more specific codes. Given the short length and press release format, RNS is the best fit among the available options for a general corporate communication.
2023-04-18 French
Pharnext supports the online 2023 Conference of CMTUK, the UK's Charity dedicated to supporting people living with Charcot-Marie-Tooth disease
Regulatory Filings Classification · 1% confidence The document is a press release dated April 18th, 2023, announcing that the company, Pharnext, supports the online 2023 Conference of CMTUK. It details the dates and purpose of the conference and provides company background. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). It is an announcement regarding company activities and engagement with a patient community/medical professionals. Since it doesn't fit the specific categories like AGM-R, DVA, DIV, or ER, and it is a general corporate announcement, the most appropriate classification is the general Regulatory Filings category (RNS), which serves as a fallback for miscellaneous regulatory or corporate news releases that don't fit elsewhere, although it is closer to general corporate news than a mandatory regulatory filing. Given the options, RNS is the best fit for a general corporate announcement/news release.
2023-04-18 English
Regroupement des actions Pharnext et suspension des conversions
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing a corporate action: a share consolidation (regroupement des actions) at a ratio of 1 new share for 10,000 old shares, including suspension of warrant exercise. This action directly impacts the company's capital structure and share count. This falls under the definition of Capital/Financing Update (CAP), as it involves a change in the capital structure, although it is not a fundraising event. It is more specific than a general Regulatory Filing (RNS) and does not fit other categories like ER, IR, or 10-K. Since it is a direct announcement about changing the number of shares outstanding and the ISIN, 'Share Issue/Capital Change' (SHA) is the most precise fit, as share consolidation is a form of capital restructuring.
2023-03-24 French
Findings on the impact of fatigue on patients living with Charcot-Marie-Tooth diseases from 'Real-World' digital lifestyle study, CMT and Me, to be presented in a webinar organized with CMT UK
Regulatory Filings Classification · 1% confidence The document is a press release from Pharnext SCA announcing that findings from their 'CMT&Me' digital study regarding Charcot-Marie-Tooth diseases will be presented in an upcoming webinar. It details the date, time, presenter, and topic of the webinar, and provides background information on the study and the disease. This is not a formal regulatory filing (like 10-K, IR, or ER), nor is it a presentation (IP) or a transcript (CT). It is an announcement about an event where information will be shared. Since it is an announcement regarding company activities and data presentation, and it doesn't fit the specific categories like Director's Dealing, Dividend Notice, or Capital Change, it falls best under the general 'Regulatory Filings' (RNS) category as a general corporate announcement, or potentially a Report Publication Announcement (RPA) if the webinar presentation itself were considered the 'report'. Given the content is an announcement of a presentation/webinar, RNS is the most appropriate general category for non-standard corporate news releases.
2023-03-23 English
Des données sur l'impact de la fatigue chez les patients atteints de maladies de Charcot-Marie-Tooth, issues de l'étude digitale CMT and Me, seront présentées lors d'un webinar organisé avec CMT UK
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces that data from the CMT&Me digital study regarding fatigue in Charcot-Marie-Tooth patients will be presented during an upcoming webinar. It details the date, time, participants, and registration link for this event. This type of announcement, which publicizes an upcoming event where information (like study results) will be shared, fits best under the category of a general regulatory announcement or news release that doesn't correspond to a specific financial report (like 10-K, ER, or IR). Since it is a press release announcing an event/data presentation rather than the presentation itself or a formal financial filing, the most appropriate general category is Regulatory Filings (RNS), as it serves as a broad communication to the market about company activities and data dissemination, especially when a more specific category like 'Investor Presentation' (IP) or 'Earnings Release' (ER) is not applicable to an external webinar announcement.
2023-03-23 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.